Harbinger Health
Harbinger Health is pioneering the detection of early cancer through innovative blood-based tests. The company combines artificial intelligence with proprietary insights into cancer biology to identify cancer before it becomes symptomatic. Founded in 2021 and incubated within Flagship Pioneering, Harbinger aims to make early cancer detection accessible and affordable for everyone, fundamentally transforming cancer care. Their approach focuses on identifying biological programs present in the earliest forms of cancer, enabling proactive interventions and potentially changing the landscape of cancer diagnosis and management.
Harbinger Health
Harbinger Health is pioneering the detection of early cancer through innovative blood-based tests. The company combines artificial intelligence with proprietary insights into cancer biology to identify cancer before it becomes symptomatic. Founded in 2021 and incubated within Flagship Pioneering, Harbinger aims to make early cancer detection accessible and affordable for everyone, fundamentally transforming cancer care. Their approach focuses on identifying biological programs present in the earliest forms of cancer, enabling proactive interventions and potentially changing the landscape of cancer diagnosis and management.
TL;DR
Focus: Blood-based early cancer detection using AI and biological insights
Founded: 2021
Headquarters: Cambridge, Massachusetts
Total funding: USD 190,000,000
Most recent round: Series B, USD 140,000,000 (Sep 28, 2023)
Company Overview
Problem Domain
Early cancer detection; oncology diagnostics; liquid biopsy
Founded
2021
Industry
Biotechnology
Tech Stack
Funding Track Record
USD 140,000,000
Round included institutional investors such as Pictet, Partners Investment, Catalyst, and M&G Investments.
Investor Signal
“Flagship Pioneering as founder and lead/backing investor; participation from global institutional investors including Pictet, Partners Investment, Catalyst, and M&G Investments”